Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
A number of studies have shown that various K vitamins, specifically vitamins K2 and K3, possess antitumor activity on various types of rodent- and human-derived neoplastic cell lines. In the present study, we examined the antitumor effects of vitamins K1, K2 and K3 on PLC/PRF/5 human hepatocellular carcinoma (HCC) cells in vitro and in vivo. Furthermore, we examined the mechanisms of antitumor actions of these vitamins in vitro and in vivo. Although vitamin K1 did not inhibit proliferation of PLC/PRF/5 cells at a 90-microM concentration (the highest tested), vitamins K2 and K3 suppressed proliferation of the cells at concentrations of 90 and 9 microM, respectively. By flow cytometric analysis, it was shown that not only vitamin K1, but also vitamin K2 did not induce apoptosis or cell cycle arrest on PLC/PRF/5 cells. In contrast, vitamin K3 induced G1 arrest, but not apoptosis on PLC/PRF/5 cells. Subsequent in vivo study using subcutaneous HCC-bearing athymic nude mice demonstrated that both vitamins K2 and K3 markedly suppressed the growth of HCC tumors to similar extent. Protein expression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4), but not p16INK4a Cdk inhibitor in the tumor was significantly reduced by vitamin K2 or K3 treatment, indicating that vitamins K2 and K3 may induce G1 arrest of cell cycle on PLC/PRF/5 cells in vivo. Taken collectively, vitamins K2 and K3 were able to induce potent antitumor effects on HCC in vitro and in vivo, at least in part, by inducing G1 arrest of the cell cycle. The results indicate that vitamins K2 and K3 may be useful agents for the treatment of patients with HCC.
Hitomi
Misuzu
M
Third Department of Internal Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan.
Yokoyama
Fumi
F
Kita
Yuko
Y
Nonomura
Takako
T
Masaki
Tsutomu
T
Yoshiji
Hitoshi
H
Inoue
Hideyuki
H
Kinekawa
Fumihiko
F
Kurokohchi
Kazutaka
K
Uchida
Naohito
N
Watanabe
Seishiro
S
Kuriyama
Shigeki
S
D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D051379:Mice; D008819:Mice, Nude; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D010837:Vitamin K 1 / Q000494:pharmacology*; D024482:Vitamin K 2 / Q000494:pharmacology*; D024483:Vitamin K 3 / Q000494:pharmacology*
D000933:Antifibrinolytic Agents; D024482:Vitamin K 2; D024483:Vitamin K 3; D010837:Vitamin K 1